Group 1 - The core theme of the conference was "innovation-driven," highlighted by the success story of the first small molecule targeted anti-cancer drug, Camrelizumab, developed by Betta Pharmaceuticals, which took nearly a decade from initiation in 2002 to market launch in 2011 [1] - The biopharmaceutical industry is experiencing unprecedented innovation opportunities due to the continuous change in disease patterns, which current treatment methods cannot fully address [2] - The integration of big data and artificial intelligence (AI) is revolutionizing new drug development, reducing the average research and development cycle and costs by approximately 50% [2] Group 2 - In the past year, China approved 76 innovative drugs and medical devices, with a total transaction value of over $130 billion for innovative drug licensing, marking a historical high and establishing China as a global source of pharmaceutical innovation [3] - The biopharmaceutical industry in Hangzhou is characterized by a collaborative ecosystem, with various stakeholders providing support to overcome challenges in drug development, particularly in preclinical research and clinical translation [4] - The Hangzhou Capital Group is actively supporting enterprises with core technologies and development potential, providing stable financial resources to facilitate innovation throughout the entire lifecycle of companies [4] Group 3 - Local institutions, including the Hangzhou Biobank and Tigermed, are committed to enhancing collaboration in resource sharing, professional services, and research platform construction to strengthen the innovation foundation of Hangzhou's biopharmaceutical industry [5]

Core Viewpoint - Beida Pharmaceutical's subsidiary, Hangzhou Jingyao Biotechnology, has received approval from the National Medical Products Administration (NMPA) for clinical trials of BPI-572270 capsules aimed at treating patients with advanced malignant solid tumors [1][2]. Group 1: Company Developments - Beida Pharmaceutical's subsidiary, Hangzhou Jingyao Biotechnology, has been granted a clinical trial approval notice by NMPA for BPI-572270 [1]. - BPI-572270 is a novel compound developed by the company, possessing complete independent intellectual property rights [2]. Group 2: Product Details - BPI-572270 is a new type of potent pan-RAS non-degradable molecular glue inhibitor [2]. - The mechanism of action involves inducing the binding of the chaperone protein Cyclophilin A (CYPA) to activated RAS mutant proteins, leading to conformational changes that prevent RAS from interacting with downstream signaling proteins, thereby blocking tumor growth pathways like MAPK [2]. - Preclinical studies indicate that BPI-572270 effectively inhibits various tumor cells with different RAS mutations, including pancreatic cancer, non-small cell lung cancer, and colorectal cancer, while also demonstrating excellent pharmacokinetic properties and good safety [2]. - The compound shows promise for single-agent treatment of multiple RAS-mutant cancers or for achieving more comprehensive disease control through combination therapy [2].

Core Viewpoint - Beida Pharmaceutical's subsidiary, Hangzhou Jingyao Biotechnology, has received approval from the National Medical Products Administration (NMPA) for clinical trials of BPI-572270 capsules aimed at treating patients with advanced malignant solid tumors [1][2]. Group 1 - BPI-572270 is a novel compound developed by the company, possessing complete intellectual property rights, and is classified as a new type of potent pan-RAS non-degradable molecular glue inhibitor [2]. - The mechanism of action involves inducing the chaperone protein Cyclophilin A (CYPA) to bind to activated RAS mutant proteins, causing conformational changes that prevent RAS from interacting with downstream signaling proteins, thereby blocking MAPK signaling pathways responsible for tumor growth [2]. - Preclinical studies indicate that BPI-572270 exhibits strong inhibitory effects on various tumor cells harboring RAS mutations (including KRAS, NRAS, HRAS) across multiple cancer types such as pancreatic cancer, non-small cell lung cancer, and colorectal cancer, while also demonstrating excellent pharmacokinetic properties and good safety [2]. Group 2 - The drug has the potential to treat multiple RAS-mutant cancers as a monotherapy or in combination with other treatments for more comprehensive disease control [2].

Core Viewpoint - The announcement indicates that the drug candidate BPI-572270, developed by the company's wholly-owned subsidiary Jingyao Biotech, has received approval from the National Medical Products Administration for clinical trials in patients with advanced malignant solid tumors [1] Group 1: Drug Development - BPI-572270 is a new molecular entity that the company has independently developed and holds complete intellectual property rights [1] - It is characterized as a novel and potent pan-RAS non-degradable molecular glue inhibitor [1] Group 2: Mechanism of Action - The mechanism of action involves inducing the chaperone protein Cyclophilin A (CYPA) to bind to activated mutant RAS proteins, leading to conformational changes in RAS proteins [1] - This process prevents RAS proteins from binding to downstream signaling proteins, such as cRAF, thereby blocking the MAPK signaling pathways responsible for tumor growth [1]

证券代码：300558 证券简称：贝达药业 公告编号：2026-002 贝达药业股份有限公司 产品名称：BPI-572270 胶囊 受理号：CXHL2501284、CXHL2501285、CXHL2501286、CXHL2501287 通知书编号：2026LP00244、2026LP00245、2026LP00246、2026LP00247 注册分类：化学药品 1 类 申请事项：境内生产药品注册临床试验 申请人：杭州景曜生物科技有限责任公司 结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 11 月 21 日受理的 BPI-572270 胶囊符合药品注册的有关要求，同意本品单药在晚期恶 性实体瘤患者中开展临床试验。 二、该临床试验用药的研究情况 BPI-572270 是由公司自主研发并拥有完全自主知识产权的新分子实体化合物， 是一种新型强效的泛 RAS"非降解型分子胶"抑制剂。其作用机制是诱导肿瘤细 胞中广泛表达的伴侣蛋白 Cyclophilin A（CYPA）结合到激活状态的 RAS 突变蛋 关于 BPI-572270 胶囊获得临床试验批准通知书的公告 本公司及董事会全体成员保证信息披 ...

[Table_Reportdate] 2026年01月27日 [证券分析师： Table_Authors] 张季恺 S0630521110001 zjk@longone.com.cn 证券分析师： 王洋 S0630513040002 wangyang@longone.com.cn 联系人： 陈伟业 cwy@longone.com.cn 联系人： 邓尧天 dytian@longone.com.cn [晨会纪要 Table_NewTitle] 20260127 重点推荐 财经要闻 晨 会 纪 要 证券研究报告 HTTP://WWW.LONGONE.COM.CN 请务必仔细阅读正文后的所有说明和声明 [table_summary] ➢ 1.药品零售新政出台，赋能行业高质量发展——医药生物行业周报（2026/01/19- 2026/01/25） ➢ 2.2026年全球AI服务器出货同比有望增超28%，AI相关芯片涨价持续——电子行业周报 2026/1/19-2025/1/25 ➢ 1.商务部：将优化实施消费品以旧换新，促进家电等大宗耐用商品消费 ➢ 2.上期所调整白银、锡期货相关合约交易限额 ➢ 3.香港特别行政区行 ...

Core Viewpoint - The innovative drug sector experienced a significant surge in 2025, with multiple innovative drug ETFs seeing annual gains exceeding 50% and several companies doubling their stock prices. However, since September 2025, both A-shares and Hong Kong stocks in this sector have faced notable corrections, with some stocks nearly halving in value. The market is now focusing on the quality of business development (BD) transactions rather than just their existence [5][6][7]. Group 1: Market Trends and Reactions - In 2025, the innovative drug sector's market capitalization reached approximately 3 trillion yuan, driven by significant BD transactions [5]. - The market's initial enthusiasm for BD transactions has waned, as investors realize that these transactions often provide only temporary cash flow improvements rather than sustainable profitability [6][7]. - The focus has shifted from merely having BD transactions to assessing their quality, which is crucial for investment decisions in innovative drugs [8]. Group 2: High-Quality BD Transactions - High-quality BD transactions are characterized by three main anchors: the certainty of target value realization, the feasibility of milestone payments, and the strength of the partner company, particularly multinational pharmaceutical firms [10]. - An example of a successful BD transaction is the collaboration between Rongchang Biopharmaceutical and AbbVie, which led to a significant stock price increase due to the validated target of the drug involved [11][13]. - Conversely, a BD transaction involving Haikang Pharmaceutical and AirNexis did not yield positive market reactions due to the lower credibility of the partner and the insufficient cash component of the upfront payment [18][20][21]. Group 3: Company Performance and Investment Opportunities - Companies like Baijie and Hengrui have shown promising performance, with Baijie leading in innovative drug revenue and expected to turn profitable in 2025, while Hengrui has successfully transitioned to an innovative drug-focused business model [34][37]. - Hansoh Pharmaceutical has also achieved profitability, with a significant portion of its revenue coming from innovative drugs, indicating a successful transformation [40]. - Companies such as Xinda Biopharmaceutical and Sanofi have potential for future profitability, with Xinda expected to launch a promising product that could significantly impact its financials [43][48]. Group 4: Selection Criteria for Investment - The selection process for investment should involve identifying companies with a high proportion of innovative drug revenue (at least 50%), assessing their profitability, and evaluating the quality of their BD collaborations and global competitiveness of their pipelines [30][31]. - The analysis of the top 15 companies by innovative drug revenue shows that 13 have over 50% of their revenue from innovative drugs, highlighting a strong focus on innovation within the sector [32]. Group 5: Future Outlook - The innovative drug industry remains attractive, but the market's valuation criteria have evolved to prioritize the quality of BD transactions and the underlying performance of companies [58]. - Continuous monitoring of companies' clinical pipeline progress and BD transaction outcomes will be essential for assessing future market activity and investment potential [58].

Core Viewpoint - Yifang Biotechnology has submitted an application for a mainboard listing on the Hong Kong Stock Exchange, amid a wave of License-out deals in the domestic innovative drug sector, but faces significant challenges including ongoing losses, business model risks, and governance concerns [1][7]. Business Model and Financial Performance - Yifang Biotechnology relies heavily on the License-out model, with its two marketed products, Beifuzi and Goresir, exclusively licensed to leading companies, BeiGene and Zhenhua Tianqing [2][8]. - Revenue figures show that from 2023 to the first three quarters of 2025, the company generated revenues of CNY 186 million, CNY 169 million, and CNY 30.89 million, all from licensing agreements [2][8]. - In 2023, over 96% of revenue came from a CNY 180 million milestone payment for Beifuzi, while in 2024, the focus shifted to a CNY 151 million milestone payment for Goresir [2][8]. - Despite these revenues, the company has not achieved profitability, reporting net losses of CNY 284 million, CNY 240 million, and CNY 181 million for 2023, 2024, and the first three quarters of 2025, respectively [2][8]. Accounts Receivable Issues - A significant issue arose when BeiGene delayed a CNY 180 million milestone payment for Beifuzi, leading to a nearly two-year overdue situation [3][9]. - Although the revenue was recognized in 2023, cash flow was delayed, resulting in a CNY 18 million bad debt provision in 2024 [3][9]. Financial Position and Fundraising - As of September 30, 2025, Yifang Biotechnology had CNY 670 million in cash and cash equivalents, CNY 700 million in time deposits, and CNY 153 million in financial assets, totaling CNY 1.523 billion in liquid assets [4][10]. - The company has CNY 1 billion of unutilized funds from its previous fundraising round and has invested CNY 761 million in cash management [4][10]. - Despite a strong cash position, the rationale for seeking additional fundraising is questioned [4][10]. Governance and Shareholding Structure - The company's governance structure is under scrutiny, with a trend of shareholding dilution following the expiration of a joint action agreement among key executives [5][11]. - The combined shareholding of the founders decreased from 28.58% to 27.26% after the agreement ended, raising concerns about control [5][11]. - A significant number of shares (approximately 161 million, or 27.79% of total shares) will be unlocked in January 2026, potentially leading to market pressure [5][11]. Executive Compensation - The total annual salary for key executives exceeded CNY 25 million from 2023 to 2024, which is considered high relative to the company's ongoing losses [6][12]. - Balancing executive incentives with shareholder returns and sustainable development remains a governance challenge [6][12].

消息面上，商务部等九部门发布关于促进药品零售行业高质量发展的意见提出，优化药品营销体系。倡 导医药生产企业与全国或区域大型医药流通企业深度合作，以市场为导向规范药品购、销价格体系，促 进药品零售行业跨省、跨地区公平竞争，引导零售药品价格保持合理水平。鼓励创新药、参比制剂等药 品进零售药店销售渠道。鼓励医药电商平台开放数据接口，加强线上、线下药品零售价与省级医药采购 平台挂网价的联动监测，加强定点药店医保药品量价比较指数和药品比价小程序的推广应用。 江海证券表示，我们认为随着全球生物医药投融资环境逐步回暖，中国创新药企业出海已成为核心发展 趋势。新年首周，国内创新药领域便落地5项对外授权合作，涵盖小分子抑制剂、单抗、双抗、ADC和 RDC等多个技术领域，充分展现了中国在生物医药各技术领域的全球领先布局实力。 （文章来源：21世纪经济报道） 1月23日，A股三大指数集体上涨，中证创新药产业指数截至发稿上涨1.37%，该指数成分股中，昭衍新 药上涨超5%，贝达药业、君实生物-U、荣昌生物、泰格医药、沃森生物等跟涨。 相关ETF方面，创新药ETF（159992）截至发稿涨1.17%，成交额超1.5亿元，盘中交投活跃。 ...

Core Insights - The report emphasizes the importance of discovering investment opportunities with a proactive attitude rather than merely relaying information [1] Macro News Summary - The Ministry of Industry and Information Technology (MIIT) supports local governments in building future industries and increasing government investment fund efforts [4] - MIIT will promote collaborative innovation across the entire supply chain for advanced materials [4] - The Ministry of Housing and Urban-Rural Development supports reasonable financing needs of real estate companies and addresses both rigid and improved housing demands of residents [4] Industry Developments - Glass substrates are expected to become the next generation of core materials for advanced packaging, replacing traditional organic substrates, with related stocks including Di'er Laser (300776) and Hongtian Co., Ltd. (603800) [5] - Six departments have extended tax and fee incentives for the childcare industry, indicating a potential boom for the maternal and infant sector, with related stocks including Kidswant (301078) and Aiyingshi (603214) [5] - Several banks have recently launched satellites, accelerating the operational value of the satellite industry, with related stocks including Hangyu Micro (300053) and Aerospace Hongtu (688066) [5] Company Focus - Ruike Laser (300747) is taking measures to resist malicious low-price sales and irregular channel sales that disrupt market pricing [6] - Betta Pharmaceuticals (300558) is progressing steadily with multiple clinical studies for MCLA-129 [6] - Zhongke Chuangda (300496) has reached a strategic cooperation with the Beijing Humanoid Robot Innovation Center through its subsidiary Xiaowu Intelligent [6] - Ningbo Bank (002142) is continuously accumulating differentiated competitive advantages, with a steady expansion of profit scale expected by 2025 [6] Market Review and Outlook - On January 21, the market experienced a pullback after a rise, with the Shanghai Composite Index closing at 4116.94, up 0.08%, and the Shenzhen Component Index at 14255.13, up 0.70% [7] - The total trading volume in the Shanghai and Shenzhen markets was 2.6 trillion, a decrease of 177.1 billion from the previous trading day [7] - The market is expected to shift from a "fund-driven" rapid growth model to a "performance-driven" slow bull market, with macroeconomic improvements and corporate profit recoveries as key drivers for mid-term upward trends [7] - It is advised to maintain balanced allocations across sectors, focusing on non-ferrous metals, technology growth, new energy, and dividend stocks [7]